Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 1/2 2Phase NA 1Phase 3 1

Status

Completed 11Terminated 2Unknown 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1CNS 1

Conditions

Mouth Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Fenretinide × Clear all
NCT00075491 2013-01-24

Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2 Terminated
42 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00003223 2012-07-24

SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth

SWOG Cancer Research Network

Phase 2 Terminated
5 enrolled
Head & Neck

Head and Neck Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡